财中社12月12日电远大医药（00512）发布自愿性公告，宣布其全球创新的血管内双模成像系统NOVASYNC近日获得中国国家药品监督管理局颁发的医疗器械注册证书。该产品为进口血管内双模成像设备NOVASIGHT的国产迭代，标志着公司成功完成了技术转移和全面国产化，这在心脑血管精准介入诊疗领域具有里程碑意义。
NOVASYNC融合了光学相干断层成像（OCT）和血管内超声（IVUS）两种成像技术，能够同时展示血管内的超声及光学图像，为医生提供更精准的治疗方案，并减少患者的医疗负担。根据专家预测，未来PCI手术量将以超过10%的增速快速增长，且中国PCI手术中IVUS和OCT技术的渗透率仍低于美国和日本等国家，表明市场存在巨大的增长空间。
公司在心脑血管精准介入诊疗领域已布局20款产品，其中14款已在中国获批上市，并与多国临床中心或研发平台进行技术合作，致力于将该领域打造成全球领先的诊疗平台。公司将继续加大对创新产品和先进技术的研发投入，以满足尚未满足的临床需求。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.